



INHIBIREF X9222

Efficient anticoagulant testing world-wide

HAEMATEx.COM

RUO - RESEARCH / INVESTIGATIONAL USE ONLY

INTENDED USE

InhibiRef provides a pre-determined quantity of coagulation inhibitors – dabigatran, edoxaban, rivaroxaban, apixaban and heparin for delivery to a blood, plasma or urine sample. They allow laboratories to prepare inhibitor samples at any concentration in any biological fluid for use in research, teaching, or other purposes.

INTRODUCTION

DOACs and other anticoagulants are usually provided in freeze dried normal plasmas for reconstitution with water and use as calibrators or in quality control. InhibiRef provides an alternative way for laboratories to access such agents for multiple uses.

DOACs are provided with as concentrates at 40 µg/ml target quantities and heparin as 30 IU/ml when reconstituted in 1 ml distilled water. Each vial is coloured for simple identification.

INSTRUCTIONS FOR USE

1.	Reconstitute vial with 1 ml distilled water for 40 µg/ml.
2.	Add required volume for desired concentration in test sample, usually 0.01 ml/ml for 400 ng/ml.
3.	Mix briefly.
4.	Inhibitor spiked test samples are ready for analysis.

CONTENTS OF PRODUCT

Product Code	Target Value per vial	Colour Code	Pack Size
X9222-D	40 µg/ml	Blue	1 Dabi-Ref
X9222-E	40 µg/ml	Yellow	1 Edoxa-Ref
X9222-R	40 µg/ml	Light Green	1 Riva-Ref
X9222-A	40 µg/ml	Dark Green	1 Apixa-Ref
X9222-H	30 IU/ml	Red	1 Heparin-Ref
X9222-SET			5 Vials- 1 of each DERAH

PRECAUTIONS

InhibiRef are strictly for *in vitro* use. If appropriate test results are not as expected. Contact your distributor or manufacturer for technical support.

Store at 2-8°C. Do not use after the expiry date indicated on the label. Treat all clinical material as potentially infectious and dispose of in accordance with local operating regulations. For further information, please refer to Safety Data Sheet and Product Information.

APPLICATION

Plasmas treated with Inhibitors may be used as positive controls in clotting, chromogenic or other assays. Targeted conc can be prepared in pooled normal plasma. For example, to get a conc. of 400 ng/ml in 0.5 ml of pooled normal plasma, 5 ul of InhibiRef can be added to 495 ul of plasma. Consensus values can be established from interlaboratory testing surveys (in progress).

Samples prepared from InhibiRef can be used for checking the efficacy of DOAC Stop™ (1). This minitab removes DOACs from test samples relatively specifically (2). Thus, samples prepared with DOACs from InhibiRef should show restoration to original test results after treatment with DOAC-Stop™. Conversely, results on samples prepared with Heparin Ref should not be modified by DOAC-Stop™.

LIMITATIONS

The agents used in InhibiRef are not endorsed by the known manufacturers of the indicated agents. The quantity of each compound shown is our "target" value and may vary within +/- 10%.

PERFORMANCE CHARACTERISTICS


Repetition testing indicates that activity of inhibitors from InhibiRefs varies by less than +/- 5% for DOACs as tested by the Russells Viper Venom (RVV)-based Go-DOAC™ test (Haematex) and similarly for heparin using APTT (Intrinsic LR) tests. The use of dRVV-based clotting tests for DOACs is strongly recommended as these are more sensitive to DOACs than most other tests (3).

INDEMNITY NOTICE

InhibiRef is strictly research use only product. Follow procedures and refer to precautions that may affect the stated or implied claims and performance of this product. Haematex Research Pty Ltd and its agents or distributors are not liable for damages.

REFERENCES

- [1] Simple method for removing DOACs from plasma samples. Exner T, et al. Thrombosis Research. 2018; 16:1028-39.
- [2] Effect of an activated charcoal product (DOAC-Stop™) intended for extracting DOACs on various other APTT-prolonging agents. Exner T, et. al. Clin Chem Lab Med. 2019; 57: 690-696.
- [3] Testing for new oral anticoagulants with LA-resistant Russell Viper Venom reagents. An invitro study. Thromb. Haematol. 2013; 109:762-765.



HTX.InhibiRefs.130624V4